Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

EO-9 bladder instillations: formulation selection based on stability characteristics and in vitro simulation studies.

S C van der Schoot1, L D Vainchtein, J H Beijnen

  • 1Department of Pharmacy & Pharmacology, Slotervaart Hospital, The Netherlands Cancer Institute, Louwesweg 6, 1066 EC Amsterdam, The Netherlands. apsvs@slz.nl

International Journal of Pharmaceutics
|October 3, 2006
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Health-related quality of life of patients with metastatic melanoma treated with tumor-infiltrating lymphocytes compared with ipilimumab in a randomized phase III trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial.

Immuno-oncology technology·2022
Same author

Posttreatment Imaging in Patients with Head and Neck Cancer without Clinical Evidence of Recurrence: Should Surveillance Imaging Extend Beyond 6 Months?

AJNR. American journal of neuroradiology·2020
Same author

The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs.

Nature·2019
Same author

Pegfilgrastim: More Cost Effective and Equally Efficacious Option as Compared to Filgrastim in Autologous Stem Cell Transplant.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion·2019
Same author

Engraftment Syndrome: Clinical Features and Predictive Factors in Autologous Stem Cell Transplant.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion·2018

Researchers developed improved formulations for EO-9 (EOquin), a bladder cancer treatment. The most stable freeze-dried formulation containing EO-9, HPbetaCD, and Tris was selected for further development based on stability testing.

Area of Science:

  • Pharmaceutical Sciences
  • Oncology
  • Drug Delivery

Background:

  • Superficial bladder cancer is treated with EO-9 (EOquin) via bladder instillation.
  • Current EO-9 formulations require improvement for pharmaceutical properties and clinical acceptability.

Purpose of the Study:

  • To develop and evaluate alternative EO-9 formulations for enhanced stability and clinical use.
  • To identify the most stable EO-9 formulation for further pharmaceutical development.

Main Methods:

  • Three freeze-dried EO-9 formulations using HPbetaCD, Tris, and NaHCO(3) were prepared.
  • Stability studies included freeze-dried products, reconstituted/diluted solutions, and simulated bladder instillation with urine.
  • Degradation products were identified.

Related Experiment Videos

Main Results:

  • The EO-9/HPbetaCD/Tris (4/600/1mg/vial) formulation demonstrated the highest stability as a freeze-dried product.
  • All formulations were stable for at least 8 hours after reconstitution and dilution.
  • Formulations were unstable in urine at pH 4 and 6, degrading into EO-5a and EO-9-Cl, but stable at pH 8.

Conclusions:

  • The EO-9/HPbetaCD/Tris formulation is the most promising for further pharmaceutical development.
  • Formulation stability is influenced by pH, particularly in urine.
  • Optimized formulations can improve the clinical viability of EO-9 for bladder cancer treatment.